Results 41 to 50 of about 100,010 (342)
Antibody–Drug Conjugates: The Last Decade
An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm.
Nicolas Joubert +3 more
doaj +1 more source
Nanoparticles for live cell microscopy: A surface-enhanced Raman scattering perspective. [PDF]
Surface enhanced Raman scattering (SERS) nanoparticles are an attractive alternative to fluorescent probes for biological labeling because of their photostability and multiplexing capabilities.
Candas, Demet +7 more
core +1 more source
Blood-brain barrier transport kinetics of NOTA-modified proteins : the somatropin case [PDF]
BACKGROUND: Chemical modifications such as PEG, polyamine and radiolabeling on proteins can alter their pharmacokinetic behaviour and their blood-brain barrier (BBB) transport characteristics. NOTA, i.e. 1,4,7-triazacyclononane-1,4,7-triacetic acid, is a
Bracke, Nathalie +7 more
core +1 more source
Histone-modifying enzymes (HMEs) are critical regulators of tumorigenesis through epigenetic reprogramming. While mutations in HMEs are recognized drivers of cancer epigenome dysregulation, systematic comparative analyses of their mutational impacts and ...
Tengjiao Li +6 more
doaj +1 more source
Cancer targeting with biomolecules: a comparative study of photodynamic therapy efficacy using antibody or lectin conjugated phthalocyanine-PEG gold nanoparticles [PDF]
The functionalisation of therapeutic nanoparticle constructs with cancer-specific biomolecules can enable selective tumour accumulation and targeted treatment. Water soluble gold nanoparticles (ca.
Allen +49 more
core +1 more source
Function‐driven design of a surrogate interleukin‐2 receptor ligand
Interleukin (IL)‐2 signaling can be achieved and precisely fine‐tuned through the affinity, distance, and orientation of the heterodimeric receptors with their ligands. We designed a biased IL‐2 surrogate ligand that selectively promotes effector T and natural killer cell activation and differentiation. Interleukin (IL) receptors play a pivotal role in
Ziwei Tang +9 more
wiley +1 more source
Antibody-Drug Conjugates in Solid Tumors
Solid tumors account for approximately 90% of all types of cancer. For many tumor types, the availability of effective treatment options is limited and new targeted approaches that offer the potential for long-term survival are warranted.
Ilaria Colombo, Alfred Zippelius
doaj +1 more source
Cutaneous Lymphoma and Antibody-Directed Therapies
The introduction of monoclonal antibodies such as rituximab to the treatment of cancer has greatly advanced the treatment scenario in onco-hematology. However, the response to these agents may be limited by insufficient efficacy or resistance.
Alvise Sernicola +3 more
doaj +1 more source
Bone metastasis in prostate cancer (PCa) patients is a clinical hurdle due to the poor understanding of the supportive bone microenvironment. Here, we identify stearoyl‐CoA desaturase (SCD) as a tumor‐promoting enzyme and potential therapeutic target in bone metastatic PCa.
Alexis Wilson +7 more
wiley +1 more source
Within the tumor microenvironment (TME), regulatory T cells (Tregs) play a key role in suppressing anticancer immune responses; therefore, various strategies targeting Tregs are becoming important for tumor therapy.
Juwon Yang, Hyunsu Bae
doaj +1 more source

